|
Autologous CD5/CD7 dual-target CAR-T module Clinical Trials
1 actively recruiting trial
Pipeline
Phase 1/2: 1
Top Sponsors
- Beijing Biotech1
Indications
- BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia1
- Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm1
- Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia1
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL1
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia1
Other1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.